Biomarker ID | 1985 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation status of RUNX3 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethlated in Recurrent prostate cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Recurrent prostate cancer Vs nonrecurrent cancer |
Type of Biomarker | Prognostic |
Cohort | Recurrence (n = 123) versus nonrecurrence (n = 75) |
Senstivity | Training: 67.4 (57.1–76.5); validation:70.4 (45.7–88.1) |
Specificity | Training: 71.7 (58.6–82.6); validation: 75.3 (50.9–91.3) |
AUC | Training: 0.746; validation: 0.788 |
Accuracy | NA |
Level Of Significance | <0.0001 |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | RUNX3 |